1. Pink Sheet
  2. >>Geography
  3. >>Asia

India’s Drug Regulatory Apparatus Set For ‘Big Ticket’ Changes

Also Looks Inward To Improve

 
• By Anju Ghangurde

India’s drugs regulator sets out plans for extensive digitization across the regulatory value chain and regulatory rationalization initiatives, while also “looking inward” to up its game as it tightens processes and enforcement. Audit action under the revised GMP norms is also being kicked off.

L-R: Nilesh Gupta, Managing Director, Lupin; Dr Rajeev Raghuvanshi, Drugs Controller General of India and Dr Arunish Chawla, Secretary, Department of Pharmaceuticals • Source: IPA

India’s drugs regulator expects to implement a raft of initiatives, including some “big ticket” items in the pipeline, as part of efforts to improve systems, processes and oversight, while also “looking inward” to up efficiencies and run a tight ship.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.